Oliver Van Oekelen

10PUBLICATIONS
44CO-AUTHORS
Molecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 24, 2024
Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria.

Sara Zhukovsky, Joshua White, Rajshekhar Chakraborty

|Sep 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Santiago Thibaud, Ryan L Subaran, Scott Newman

|Nov 03, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.

Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine

|Aug 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.

Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff

|Dec 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.

Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya

|Sep 15, 2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.

William E Pierceall, Michael D Amatangelo, Nizar J Bahlis

Pageof 2

Frequent Collaborators

4 joint publications

Tarek H Mouhieddine

3 joint publications

Hearn Jay Cho

3 joint publications

Santiago Thibaud

3 joint publications

Sundar Jagannath